This article serves as an index for STAT News' coverage of Novo Nordisk, highlighting the company's massive economic growth driven by the success of its GLP-1 agonists, Wegovy and Ozempic. It notes that the company's market capitalization has rivaled the GDP of Denmark. The provided links cover a wide range of recent topics, including legal battles with competitors like Eli Lilly and Hims & Hers, regulatory fines in France, and the ongoing debate over Medicare coverage and drug pricing.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.